A post hoc analysis of the ATTAIN-1 trial examined the efficacy and safety of orforglipron in adults with a body mass index of 27 to less than 30 kg/m² and at least one adiposity-related complication. The trial, identified by NCT05869903, was a phase 3, randomized, double-blind, placebo-controlled study.
Key Clinical Findings
Participants were randomized 3:3:3:4 to once-daily orforglipron at doses of 5.5, 9, or 17.2 mg, or placebo, for 72 weeks. The analysis included 260 participants, divided into four groups receiving orforglipron (5.5 mg, 64; 9 mg, 64; 17.2 mg, 62) and a placebo group (78). The primary endpoints assessed changes in body weight, BMI, waist circumference, lipids, patient-reported outcomes, and safety measures from baseline to Week 72.
Efficacy Results
At Week 72, orforglipron demonstrated a greater mean percent body weight reduction (17.2 mg: -13.5%) compared to placebo (-0.3%) regarding the nominal p value. This analysis focused on individuals with overweight and at least one adiposity-related complication, a group considered to be at substantial cardiometabolic risk. The results indicated improvements in anthropometric and cardiometabolic parameters with orforglipron treatment. The safety profile of orforglipron was broadly consistent with the overall findings of the ATTAIN-1 trial and involved the administration of